Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Major hepatic venous and caval injuries during hepatectomy following SIRT: a technical caution.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same author

1-2-3-4 Sign FDG PET Sign in Sarcoidosis.

Journal of medical imaging and radiation oncology·2026
Same author

Quality metrics for perioperative red blood cell transfusion in gastrointestinal cancer surgery: international Delphi consensus.

BJS open·2026
Same author

Surgical management of pancreatic neuroendocrine tumours.

The British journal of surgery·2026
Same author

Synoptic Multidisciplinary Team Meeting Workflows to Promote Guideline-Based Classification of Resectability in Pancreatic Cancer: A Multicenter Prospective Study.

JCO clinical cancer informatics·2026
Same author

Successful Management of an Abdominal Fistularising Lymphoma Without Surgery.

ANZ journal of surgery·2025

Related Experiment Video

Updated: May 27, 2026

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

68Ga-FAPI-46 PET/CT Versus 18F-FDG PET/CT for Pancreatic Cancer: A Feasibility Study.

Nicola Evans1, Ebony Perkins1, Sepinoud Firouzmand1

  • 1I-MED Radiology Network, Brisbane, Queensland, Australia.

Journal of Medical Imaging and Radiation Oncology
|May 26, 2026
PubMed
Summary

68Ga-FAPI PET/CT is a safe and effective imaging tool for pancreatic cancer, showing higher uptake and better lesion detection than 18F-FDG PET/CT. This novel approach can improve cancer staging and warrants further clinical investigation.

Keywords:
68Ga‐FAPI‐46FDG PET/CTfibroblast activation protein inhibitor (FAPI)molecular imagingpancreatic cancerstaging and re‐staging

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Experiment Videos

Last Updated: May 27, 2026

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiochemistry

Background:

  • Pancreatic cancer poses a significant diagnostic challenge.
  • Current imaging modalities like 18F-FDG PET/CT have limitations in detecting small lesions and assessing disease extent.
  • Fibroblast activation protein (FAPI) targeted radiotracers offer a promising alternative for cancer imaging.

Purpose of the Study:

  • To assess the feasibility of 68Ga-FAPI PET/CT in patients with pancreatic cancer.
  • To compare the diagnostic performance of 68Ga-FAPI PET/CT against 18F-FDG PET/CT in terms of radiotracer uptake and lesion detection.
  • To evaluate the clinical utility of 68Ga-FAPI PET/CT in staging pancreatic cancer.

Main Methods:

  • Ten participants with suspected or confirmed pancreatic cancer underwent both 68Ga-FAPI PET/CT and 18F-FDG PET/CT.
  • Imaging data were analyzed for tracer uptake (SUVmax), lesion detection capabilities, and diagnostic usefulness by clinicians.
  • Comparison focused on lesion identification, delineation, and impact on patient staging.

Main Results:

  • 68Ga-FAPI PET/CT demonstrated significantly higher maximal standardized uptake values (SUVmax) in primary pancreatic lesions compared to 18F-FDG PET/CT (mean 13.8 vs. 7.0).
  • 68Ga-FAPI PET/CT identified additional lesions in three participants, leading to upstaging in these cases.
  • Clinicians found 68Ga-FAPI PET/CT to be more diagnostically useful in five participants, with equivalent utility in the rest. Areas of inflammation also showed increased uptake.

Conclusions:

  • 68Ga-FAPI PET/CT is a safe imaging modality for pancreatic cancer with superior uptake compared to 18F-FDG.
  • The tracer's ability to detect additional lesions and influence staging supports its role as a complementary tool.
  • Larger prospective studies are required to fully establish the clinical impact of 68Ga-FAPI PET/CT in managing pancreatic cancer.